US genomic cancer profiling firm FMI heading for China, where access to new therapies lags – CNBC


CNBC

US genomic cancer profiling firm FMI heading for China, where access to new therapies lags
CNBC
China lags the U.S., Europe and regional hubs such as Singapore and Hong Kong on access to cutting-edge cancer drugs, but the mainland will soon get a glimpse of potential next-generation targeted therapies as U.S.-listed genomicsequencing firm …

and more »

Source: Genome Sequencing